Published On: Wed, Oct 19th, 2016

Kamada Ltd. (NASDAQ:KMDA) Analyst Review


A number of investment brokers have recently updated their price targets on shares of Kamada Ltd. (NASDAQ:KMDA).

Most recent broker ratings

09/01/2016 – Kamada Ltd. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 10 price target on the stock.

08/31/2016 – Kamada Ltd. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 7 price target on the stock.

05/15/2015 – Kamada Ltd. was downgraded to “sell” by analysts at Zacks.

01/07/2015 – Kamada Ltd. had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 8 price target on the stock.

07/08/2014 – Oppenheimer began new coverage on Kamada Ltd. giving the company a “market perform” rating.

The share price of Kamada Ltd. (NASDAQ:KMDA) was down -3.88% during the last day of trading, with a day high of 5.56. 108576 shares were traded during the last session.

The stock’s 50 day moving average is 5.09 and its 200 day moving average is 4.20. The stock’s market capitalization is 198.48M. Kamada Ltd. has a 52-week low of 3.26 and a 52-week high of 5.86.

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.